A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Recruiting

Phase 1

Phase 2

OC-001A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Sponsor:

Ocellaris Pharma, Inc.

Code:

NCT04260802

Conditions

Cancer

Neoplasms

Metastatic Cancer

Triple Negative Breast Cancer

Gastric Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

OC-001

Drug: OC-001 in Combination with Avelumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-12. This information was provided to ClinicalTrials.gov by Ocellaris Pharma, Inc. on 2025-07-20.